Effects of chronic HBV infection on human hepatic cytochrome P450 3A4

National Medical Journal of China

Volumn 86, Issue 38, 2006, Pages 2703-2706

  Li, Shuang ^a   Hu, Zhou Han ^b   Miao, Xiao Hui ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Chromatography, high pressure liquid; Hepatitis B virus; NADPH Ferrihemoprotein reductase

Indexed keywords

CYTOCHROME P450 3A4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ADULT; ARTICLE; CENTRIFUGATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER PARENCHYMA; LIVER SURGERY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; TISSUE HOMOGENATE; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HEPATITIS B, CHRONIC; HUMANS; KINETICS; LIVER; MALE; MICROSOMES, LIVER;

EID: 33845881697     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy:pharmacodynamic and pharmacokinetic interactions. Psychosomatics, 2004, 45:84-87.
2. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet, 2002,360:1155-1162.
3. Moore JT, Moore LB, Maglich JM, et al. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta, 2003,1619: 235-238.
4. Omasa T, Kim K, Hiramatsu S, et al. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnol Prog, 2005,21: 161-167.
5. Luo G, Lin J, Fiske WD, et al. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos, 2003, 31: 1170-1175.
6. Wild CP, Yin F, Turner PC, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer, 2000, 86:1-7.
7. Di Marco A, Marcucci I, Verdirame M, et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab Dispos, 2005, 33: 349-358.
8. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001, 27: 383-391.
9. Luo G, Guenthner T, Gan LS, et al. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab, 2004, 5:483-505.
10. Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem, 2004, 4:1733-1744.
11. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit, 2004, 26:192-199.
12. Novak D, Lewis JH. Drug-induced liver disease. Curr Opin Gastroenterol, 2003, 19:203-215.
13. Guengerich FP. Cytochrome P450S and other enzymes in drug metabolism and toxicity. AAPS J, 2006,8: E101-111.
14. Chinese source. 2001,6:1.
15. Chinese source. 2002,7:217.
16. Chinese source. 2002,7:263-264.
17. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol, 2003, 43:149-173.
18. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos, 2002, 30: 883-891.